ReviewRegenerative medicine2025
Building the framework for bioprinted human heart tissue: recent developments and future prospects.
Review in Regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- 3D bioprinting of microfluidic systems for cardiac regenerative medicine: from biofabrication to organ-on-a-chip.Journal of biological engineering · 2026Review
- 3D biofabricated in vitro models as new approach methodologies for animal alternatives.npj biomedical innovations · 2026Review
- Current status, trend and progress of stem cells in tracheal tissue engineering research: an overview and perspectives.Stem cell research & therapy · 2025Review
- 3D Bioprinting Functional Engineered Heart Tissues.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac bioprinting holds great promise for creating patient-specific grafts and physiologically relevant drug-testing platforms, yet several critical challenges remain. This review identifies key barriers in current cardiac bioprinting approaches, including limitations in bioprinting precision, bioink development, vascularization, functional maturation, and scalable cell sourcing and processing. Recent advances, such as multimodal printing, hybrid bioinks, and perfusable constructs, are discussed with a focus on their application to drug discovery and graft fabrication. We emphasize that targeted maturation may suffice for drug screening, while graft applications demand greater complexity, scale, and immune compatibility. Addressing these challenges through integrated, multidisciplinary strategies will be essential to advance cardiac bioprinting toward clinical and preclinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.